Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells.

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42

Cancer. p53, guardian of the genome. Nature (1992) 16.36

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48

Divorcing ARF and p53: an unsettled case. Nat Rev Cancer (2006) 5.17

Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer (2003) 4.78

DNA damage-induced cell death by apoptosis. Trends Mol Med (2006) 4.67

Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57

The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol (2003) 4.46

Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol (1999) 4.15

Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov (2014) 2.88

Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif (2003) 2.13

Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood (2006) 2.11

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res (2005) 2.07

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood (2006) 1.71

Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res (2005) 1.52

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood (2006) 1.49

New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv (2009) 1.29

All-trans-retinoic acid nanodisks. Int J Pharm (2007) 1.23

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res (2007) 1.18

Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res (2002) 1.18

Curcumin nanodisks: formulation and characterization. Nanomedicine (2010) 1.12

Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One (2011) 1.10

O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res (2007) 1.09

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol (2013) 1.08

Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. Mol Cancer Ther (2006) 1.04

A new PICTure of nucleolar stress. Cancer Sci (2012) 0.98

Clinical Overview of MDM2/X-Targeted Therapies. Front Oncol (2016) 0.98

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Curr Drug Targets (2014) 0.98

The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai) (2014) 0.97

Nanobiotechnology applications of reconstituted high density lipoprotein. J Nanobiotechnology (2010) 0.97

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. Cold Spring Harb Perspect Med (2016) 0.92

Current trends in the surgical management and treatment of adult glioblastoma. Ann Transl Med (2015) 0.90

Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. Cancer Res (2004) 0.89

Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. Neuro Oncol (2001) 0.84

Regulation of Mutant p53 Protein Expression. Front Oncol (2015) 0.84

Recent Molecular Advances in Our Understanding of Glioma. Cureus (2015) 0.82

Identification of a hTid-1 mutation which sensitizes gliomas to apoptosis. FEBS Lett (2004) 0.82

Molecules that target nucleophosmin for cancer treatment: an update. Oncotarget (2016) 0.81

Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. J Control Release (2016) 0.78

Low-Dose Actinomycin-D Induces Redistribution of Wild-Type and Mutated Nucleophosmin Followed by Cell Death in Leukemic Cells. J Cell Biochem (2015) 0.77

The evolving roles and controversies of radiotherapy in the treatment of glioblastoma. J Med Radiat Sci (2016) 0.75